Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arvaya HealthcareBOM:524723 34 Altman Z-Score is 4.01 as of Jul. 18, 2026, which is 93% below its 10-year median of 58.08. GuruFocus rates BOM:524723 with a GF Score™ of 34/100 and a GF Value™ of ₹49.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 117 Medical Distribution companies, Arvaya Healthcare ranks better than 69.23% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.32 is strong.
Arvaya Healthcare has a Altman Z-Score of 4.01, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Arvaya Healthcare's Altman Z-Score or its related term are showing as below:
BOM:524723'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.19 Med: 58.08 Max: 111.03
Current: 3.32
During the past 13 years, Arvaya Healthcare's highest Altman Z-Score was 111.03. The lowest was 2.19. And the median was 58.08.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Arvaya Healthcare Altman Z-Score Related Terms
Arvaya Healthcare Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Arvaya Healthcare's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524723 vs MCK, CAH, COR: Altman Z-Score Comparison
For the Medical Distribution subindustry, Arvaya Healthcare's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arvaya Healthcare Altman Z-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arvaya Healthcare's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Arvaya Healthcare's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Arvaya Healthcare's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.0387
+
1.4
*
0
+
3.3
*
0.0096
+
0.6
*
6.4426
+
1.0
*
0.0648
=
4.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Arvaya Healthcare (BOM:524723) has a Altman Z-Score of 4.01 as of Jul. 18, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Arvaya Healthcare and its competitors. This is 93% below median its historical median of 58.08. Over the past decade, Arvaya Healthcare's Altman Z-Score has ranged from 2.19 to 111.03. According to the industry distribution chart, Arvaya Healthcare ranks #36 out of 117 companies in the Medical Distribution industry, placing it in the top 30.8%.
Is Arvaya Healthcare's Altman Z-Score too high?
Arvaya Healthcare's current Altman Z-Score of 4.01 is 93% below median its 10-year median of 58.08. Over the past 10 years, this metric has ranged from a low of 2.19 to a high of 111.03. The Medical Distribution industry median Altman Z-Score is 2.59. Arvaya Healthcare's value of 4.01 is 54.8% above this industry median. Based on the distribution chart, Arvaya Healthcare ranks #36 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Arvaya Healthcare has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arvaya Healthcare's Altman Z-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Arvaya Healthcare ranks #36 out of 117 companies for Altman Z-Score. This puts Arvaya Healthcare in the upper half of its industry. The industry median Altman Z-Score is 2.59. Arvaya Healthcare's value of 4.01 is 54.8% above this benchmark. Historically, Arvaya Healthcare's own Altman Z-Score has ranged from 2.19 to 111.03 over the past decade. While the company's 10-year median is 58.08 vs. the industry median of 2.59, Arvaya Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Distribution company?
The median Altman Z-Score among Medical Distribution companies is 2.59, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arvaya Healthcare's current Altman Z-Score of 4.01 is 54.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Arvaya Healthcare and its competitors. For the Medical Distribution industry, the median Altman Z-Score is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arvaya Healthcare's current Altman Z-Score is 4.01, which is 93% below median its own 10-year median of 58.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvaya Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Arvaya Healthcare (BOM:524723) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹49.41, compared to a current price of ₹104.05 — trading 110.6% above its estimated fair value. The current Altman Z-Score is 4.01, which is 93% below median its 10-year median of 58.08 and 54.8% above the Medical Distribution industry median of 2.59. Arvaya Healthcare's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Arvaya Healthcare (BOM:524723), the current Altman Z-Score is 4.01 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arvaya Healthcare (BOM:524723) Overvalued in 2026?
Based on GuruFocus' analysis, Arvaya Healthcare stock appears to be overvalued.
The current stock price of ₹104.05 is trading 110.6% above its estimated GF Value™ of ₹49.41.
GuruFocus considers Arvaya Healthcare to be Significantly Overvalued.
Key valuation signals for BOM:524723:
Altman Z-Score: 4.01 (93% below median its 10-year median of 58.08)
GF Value™: ₹49.41 vs. price of ₹104.05 (110.6% above fair value)
Industry Position: 54.8% above the Medical Distribution median (#36 of 117)
No single metric tells the full story. See the BOM:524723 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arvaya Healthcare Ltd is focused on developing an integrated healthcare platform in India that combines hospital services, diagnostics, wellness services, and digital health management solutions. Its operations include multi-specialty hospitals, a digital health platform for appointment booking and health record management, diagnostic services including laboratory testing and home sample collection, and wellness facilities offering preventive and recovery-focused programs.
34GF Score
Get the complete analysis for BOM:524723
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524723 has been successfully added to your 
